Biogen (BIIB) News Today

Biogen Inc. (NASDAQ:BIIB) has seen mixed movements as recent clinical data and analyst revisions have been offset by broader market headwinds and insider sales.

• Positive Sentiment: The company launched a Phase 3 study of felzartamab for IgAN, which could expand its rare kidney disease pipeline and drive future sales. Biogen’s New Study on Felzartamab
• Positive Sentiment: William Blair raised its Q2 2025 EPS estimate for BIIB to $4.11 from $4.09, signaling stronger near-term profitability.
• Positive Sentiment: Wedbush boosted its Q2 2025 EPS forecast to $4.15 from $3.95, reflecting higher expected earnings momentum.
• Positive Sentiment: William Blair issued an optimistic outlook for the company’s earnings, reinforcing confidence in its financial trajectory. William Blair Issues Optimistic Outlook for Biogen Earnings
• Neutral Sentiment: Analysts preview Biogen’s upcoming earnings report, highlighting key drivers such as ADUHELM and the spinal muscular atrophy franchise. Here's What to Expect From Biogen's Next Earnings Report
• Neutral Sentiment: BIIB maintains a consensus “Hold” rating from 32 brokerages, suggesting mixed analyst views. Biogen Inc. Given Consensus Rating of Hold
• Neutral Sentiment: William Blair forecasts Q3 2025 EPS at $4.03, in line with expectations and reflecting steady growth prospects. What is William Blair's Estimate for Biogen Q3 Earnings?
• Negative Sentiment: Tech stocks, including BIIB, were dragged lower by concerns over proposed tariffs, weighing on market sentiment. Tech Stocks Dip on Tariff Plans
• Negative Sentiment: Wedbush cut its Q3 2025 EPS estimate to $3.81 from $3.85, signaling potential headwinds for next quarter’s profitability.
• Negative Sentiment: Insider Rachid Izzar sold 2,223 shares at an average price of $135, reducing insider ownership by nearly 26%. Rachid Izzar Insider Sale